Skip to main content

Advertisement

Log in

Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyound anecdotal evidence?

Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Paraneoplastic neurological syndromes constitute an unusual manifestation of cancer. The objective of this case report is to debate the association between rituximab therapy and Guillain-Barre syndrome. We present the case of a 57 years old patient, with diffuse large-B cell lymphoma in complete remission, who consulted our hospital because of symmetric lower extremity weakness, developed while being treated with a rituximab maintenance schedule. Our main conclusion is that plasma cell dysregulation due to rituximab should be clarified in future studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vedeler CA. Inflammatory neuropathy: update. Curr Opin Neurol. 2000;13:305–9.

    Article  PubMed  CAS  Google Scholar 

  2. Asbury A, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine. 1969;48:173–215.

    Article  PubMed  CAS  Google Scholar 

  3. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guilain-Barre syndrome: clinical associations and outcome. Ann Neurol. 1998;44: 780–8.

    Article  PubMed  CAS  Google Scholar 

  4. Hafer-Macko C, Hsieh ST, Li GY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996;40:655–44.

    Article  Google Scholar 

  5. Winer JB, Kangro RA, Anderson MJ, Jones DM, Kangro H, Watkins RP. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry. 1988;51:613–8.

    Article  PubMed  CAS  Google Scholar 

  6. Hahn AF. Guillatin-Barre syndrome. Lancet. 1998;352(9128):635–41.

    Article  PubMed  CAS  Google Scholar 

  7. Waksman, BH, Adams RD. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med. 1955;102:213.

    Article  PubMed  CAS  Google Scholar 

  8. Vigliani MC, Magistrello M, Polo P, Mutani R, Chio A. Risk of cancer in patients with Guillain-Barre syndrome (GBS). A population-based study. Piemonte and Valle d'Aosta Register for Guillain-Barre Syndrome. J Neurol. 2004;25(3): 321–6.

    Article  Google Scholar 

  9. Zuk E, Nowacki P, Fabian A. Guillain-Barre syndrome in patient with Burkitt's lymphoma and type 2 diabetes mellitus. Folia Neuropathol. 2001;39(4):281–4.

    PubMed  CAS  Google Scholar 

  10. Toren A, Mandel M, Shahar E, Rimmoni E. Primary central newrvous system Burkitt's lymphoma presenting as Guillain-Barre syndrome. Med Pediatr Oncol. 1994; 25(4):372–5.

    Article  Google Scholar 

  11. Phan TG, Manoharan A, Pryor D. Relapse of central nervous system Burkitt's lymphoma presenting as Guillain-Barre syndrome and syndrome of inappropriate ADH secretion. Aust N Z J Med. 1998;28 (2):223–4.

    PubMed  CAS  Google Scholar 

  12. Magne N, Foa C, Castadot P, Ott J. Guillain-Barre syndrome and non-Hodgkin's lymphoma. Report of one case and review of literature. Rev Med Brux. 2005;26 (2):108–11.

    PubMed  CAS  Google Scholar 

  13. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barre syndrome in South East England. J Neurol Neurosurg Psychiatry. 1998;64:74–7.

    PubMed  CAS  Google Scholar 

  14. Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 2003;126(Pt 10): 2220–34.

    Article  PubMed  Google Scholar 

  15. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol. 2002; 51(6):673–80.

    Article  PubMed  CAS  Google Scholar 

  16. Kuwabara S. Guillain-Barre syndrome: epidemiology, pathophysiology and management. Drugs. 2004;64:597–610.

    Article  PubMed  Google Scholar 

  17. Radhakrishnan VV, Sumi MG, Reuben S, Mathai A, Nair MD. Serum tumour necrosis factor-alpha and soluble tumour necrossi factor receptors levels in patients with Guillain-Barre syndrome. Acta Neurol Scand. 2004;109:71–4.

    Article  PubMed  CAS  Google Scholar 

  18. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2++ conductance found constitutively in B-lymphocytes. J Cell Biol. 1993;121:1121–32.

    Article  PubMed  CAS  Google Scholar 

  19. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology. 1999;52:1701–4.

    PubMed  CAS  Google Scholar 

  20. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse/human monoclonal antibody to CD20. Blood 1994;83:435–45.

    PubMed  CAS  Google Scholar 

  21. Finsterer J. Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol Scand. 2005;112(2):115–25.

    Article  PubMed  CAS  Google Scholar 

  22. Lunenmann JD, Prass K, Zschenderlein R. Immunotherapy of chronic inflammatory demyelinating polyneuropathy. Fortschr Neurol Psychiatr. 2004;72:672–8.

    Article  Google Scholar 

  23. Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology. 2004;63:2178–9.

    PubMed  Google Scholar 

  24. Alwayn IP, Xu Y, Basker M, et al. Effects of specific anti-B and/or anti-plasma cell immunogherapy on antibody production in baboons: depletion of CD20- and CD22- positive B cells does not result in significantly decreased production of anti-alphaGal antibody. Xenotransplantation. 2001;8:157–71.

    Article  PubMed  CAS  Google Scholar 

  25. Rojas-García R, Gallardo E, de Andrés I, de Luna N, Juárez C, Sanchez P, Illa I. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology. 2003;61 (12):1814–6.

    PubMed  Google Scholar 

  26. Ghobrial IM, Fonseca R, Greipp PR, et al. Eastern Cooperative Oncology Group: Initial immunoglobulin M „flare” after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia-An Eastern Cooperative Oncology Group study. Cancer. 2004:101:2593–8.

    Article  PubMed  CAS  Google Scholar 

  27. Vanita Noronha, Thomas M. Fynan, Thomas Duffy. Flare in Neuropathy Following Rituximab Therapy for Waldenstrom's Macroglobulinemia JCO. 2006:e3.

  28. Buda-Okreglak EM, Drabick JJ, Delaney NR. Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab. Ann Hematol. 2004; 83:117–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alberto Carmona.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carmona, A., Alonso, J.D., de las Heras, M. et al. Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyound anecdotal evidence?. Clin Transl Oncol 8, 764–766 (2006). https://doi.org/10.1007/s12094-006-0126-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-006-0126-5

Key words

Navigation